# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k061165   
B. Purpose for Submission: New device   
C. Measurand: Anti-cyclic citrullinated peptides (CCP)   
D. Type of Test: Semi-quantitative fluoroenzymeimmunoassay   
E. Applicant: Phadia US, Inc. (formerly Sweden Diagnostics (US), Inc.)   
F. Proprietary and Established Names: EliA CCP, EliA CCP Control   
G. Regulatory Information: 1. Regulation section: 21 CFR $\ S 8 6 6 . 5 7 7 5$ Rheumatoid Factor Immunological Test System 2. Classification: Class II 3. Product code: NHX, Antibodies, Anti-cyclic citrullinated peptide 4. Panel: Immunology 82

# H. Intended Use:

1. Intended use(s): EliA CCP is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to (CCP) in human serum and plasma. The presence of antiCCP antibodies can be used in conjunction with clinical findings and other laboratory tests as an aid in the clinical diagnosis of rheumatoid arthritis (RA). EliA CCP uses the EliA IgG method on the instrument ImmunoCAP 100 [or ImmunoCAP 250].   
2. Indication(s) for use: Same as Intended Use.   
3. Special conditions for use statement(s): For prescription use   
4. Special instrument requirements: ImmunoCAP 100 or ImmunoCAP 250

I. Device Description:

The device components consist of: CCP Wells (coated with citrullinated synthetic peptides); CCP Controls: Negative, and Positive containing IgG antibodies to CCP; Sample Diluent; IgG Conjugate ( $\beta$ -Galactosidase anti-IgG mouse monoclonal antibodies; IgG Calibrators (0, 4, 10, 20, 100, $6 0 0 \mu \mathrm { g / L }$ ); IgG Curve Control; IgG Calibrator Well (coated with mouse monoclonal antibodies); Dummy Well; General Reagents (Development Solution of $1 \%$ 4-methylumbelliferyl- $\beta$ -D-galactoside, Stop

Solution of $4 \%$ sodium carbonate, and ImmunoCAP Washing Solution).

# J. Substantial Equivalence Information:

1. Predicate device name(s): Axis Shield Diagnostics, Ltd. DIASTAT Anti-CCP

2. Predicate 510(k) number(s): k023285

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>EliA CCP</td><td rowspan=1 colspan=1>DIASTAT Anti-CCP</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Semi-quantitativemeasurement of IgGantibodies directed toCCP in human serumand plasma as an aid inthe clinical diagnosis ofRA</td><td rowspan=1 colspan=1>Semi-quantitative/ qualitativeELISA for the detection of theIgG class of autoantibodiesspecific to cyclic citrullinatedpeptide (CCP) in humanserum and plasma as an aid inthe diagnosis of RA</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Synthetic citrullinatedpeptide</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Positive and negative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Solid phase</td><td rowspan=1 colspan=1>Microwells</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">EliA CCP</td><td colspan="1" rowspan="1">DIASTAT Anti-CCP</td></tr><tr><td colspan="1" rowspan="1">Method</td><td colspan="1" rowspan="1">Fluoroenzyme-immunoassay</td><td colspan="1" rowspan="1">Enzyme-linkedimmunosorbent assay</td></tr><tr><td colspan="1" rowspan="1">Instrumentation</td><td colspan="1" rowspan="1">ImmunoCAP 100 orImmunoCAP 250</td><td colspan="1" rowspan="1">ELISA plate reader with 550nm filter</td></tr><tr><td colspan="1" rowspan="1">Conjugated antibody</td><td colspan="1" rowspan="1">β-Galactosidase anti-IgG mouse monoclonalantibodies</td><td colspan="1" rowspan="1">Alkaline phosphatase-labeledmurine monoclonal antibodyto human IgG</td></tr><tr><td colspan="1" rowspan="1">Reference range</td><td colspan="1" rowspan="1">&lt;7 U/mL = negative7-10 U/mL =equivocal &gt;10 U/mL =positive</td><td colspan="1" rowspan="1">Qualitative:absorbance ratio of&lt;0.95 = negative;≥0.95- ≤1.0 = borderline; &gt;1.0 = positiveSemi-quantitative:≤5 U/mL = negative&gt;5 U/mL = positive</td></tr><tr><td colspan="1" rowspan="1">Substrate</td><td colspan="1" rowspan="1">4-methylumbelliferyl-β-D-galactoside</td><td colspan="1" rowspan="1">Phenolphthaleinmonophosphate</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Total IgG calibrators(0, 4, 10, 20, 100, 600μg/L)</td><td colspan="1" rowspan="1">Anti-CCP standards (0, 2, 8,30, 100 U/mL)</td></tr><tr><td colspan="1" rowspan="1">Signal</td><td colspan="1" rowspan="1">Fluorescence</td><td colspan="1" rowspan="1">Optical density</td></tr><tr><td colspan="1" rowspan="1">Sample diluent</td><td colspan="1" rowspan="1">PBS containing BSA,detergent and sodiumazide - ready to use</td><td colspan="1" rowspan="1">Phosphate buffer, proteinstabilizer with sodium azide -5X, dilute before use</td></tr><tr><td colspan="1" rowspan="1">Stop solution</td><td colspan="1" rowspan="1">Sodium carbonate</td><td colspan="1" rowspan="1">Sodium hydroxide</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

“Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices”

# L. Test Principle:

The EliA CCP Wells are coated with citrullinated synthetic peptides. If present in the patient’s specimen, antibodies to CCP bind to their specific antigen. After washing away non-bound antibodies, enzyme-labeled antibodies against human IgG antibodies (EliA IgG Conjugate) are added to form an antibody-conjugate complex. After incubation, non-bound conjugate is washed away and the bound complex is incubated with a Development Solution. After stopping the reaction, the fluorescence in the reaction mixture is measured. The higher the response value, the more specific IgG is present in the specimen. To evaluate test results, the response for patient samples is compared directly to the response for calibrators.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Three positive samples were measured in duplicate on one instrument in 6 runs on 3 different CCP well batches together with 3 different conjugate batches. The studies yielded the following:

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean (U/mL)</td><td rowspan=1 colspan=1>Inter-run (CV %)</td><td rowspan=1 colspan=1>Intra-run (CV %)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>18.3</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>90.7</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>419</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>5.4</td></tr></table>

$b$ . Linearity/assay reportable range:

Linearity by dilution was tested by using 5 high positive anti-CCP samples. The samples were tested in duplicates for dilutions at 1:2, 1:4, 1:8, and 1:16. The results of the dilutions were compared with their expected values and the ratios of observed-to-expected values were calculated. The following ratios were obtained.

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Mean concentration (U/mL)</td><td colspan="1" rowspan="1">O/E (ratio)</td></tr><tr><td colspan="1" rowspan="1">Sample 1</td><td colspan="1" rowspan="1">283.9</td><td colspan="1" rowspan="1">1.00</td></tr><tr><td colspan="1" rowspan="1">1:2</td><td colspan="1" rowspan="1">166.7</td><td colspan="1" rowspan="1">1.17</td></tr><tr><td colspan="1" rowspan="1">1:4</td><td colspan="1" rowspan="1">79.9</td><td colspan="1" rowspan="1">1.13</td></tr><tr><td colspan="1" rowspan="1">1:8</td><td colspan="1" rowspan="1">40.7</td><td colspan="1" rowspan="1">1.15</td></tr><tr><td colspan="1" rowspan="1">1:16</td><td colspan="1" rowspan="1">21.1</td><td colspan="1" rowspan="1">1.19</td></tr><tr><td colspan="1" rowspan="1">Sample 2</td><td colspan="1" rowspan="1">287.8</td><td colspan="1" rowspan="1">1.00</td></tr><tr><td colspan="1" rowspan="1">1:2</td><td colspan="1" rowspan="1">155.2</td><td colspan="1" rowspan="1">1.08</td></tr><tr><td colspan="1" rowspan="1">1:4</td><td colspan="1" rowspan="1">73.3</td><td colspan="1" rowspan="1">1.02</td></tr><tr><td colspan="1" rowspan="1">1:8</td><td colspan="1" rowspan="1">40.6</td><td colspan="1" rowspan="1">1.13</td></tr><tr><td colspan="1" rowspan="1">1:16</td><td colspan="1" rowspan="1">20.4</td><td colspan="1" rowspan="1">1.14</td></tr><tr><td colspan="1" rowspan="1">Sample 3</td><td colspan="1" rowspan="1">238.1</td><td colspan="1" rowspan="1">1.00</td></tr><tr><td colspan="1" rowspan="1">1:2</td><td colspan="1" rowspan="1">129.2</td><td colspan="1" rowspan="1">1.09</td></tr><tr><td colspan="1" rowspan="1">1:4</td><td colspan="1" rowspan="1">69.3</td><td colspan="1" rowspan="1">1.16</td></tr><tr><td colspan="1" rowspan="1">1:8</td><td colspan="1" rowspan="1">36.4</td><td colspan="1" rowspan="1">1.22</td></tr><tr><td colspan="1" rowspan="1">1:16</td><td colspan="1" rowspan="1">17.4</td><td colspan="1" rowspan="1">1.17</td></tr><tr><td colspan="1" rowspan="1">Sample 4</td><td colspan="1" rowspan="1">74.6</td><td colspan="1" rowspan="1">1.00</td></tr><tr><td colspan="1" rowspan="1">1:2</td><td colspan="1" rowspan="1">39.5</td><td colspan="1" rowspan="1">1.06</td></tr><tr><td colspan="1" rowspan="1">1:4</td><td colspan="1" rowspan="1">20.0</td><td colspan="1" rowspan="1">1.07</td></tr><tr><td colspan="1" rowspan="1">1:8</td><td colspan="1" rowspan="1">10.7</td><td colspan="1" rowspan="1">1.14</td></tr><tr><td colspan="1" rowspan="1">1:16</td><td colspan="1" rowspan="1">5.7</td><td colspan="1" rowspan="1">1.22</td></tr><tr><td colspan="1" rowspan="1">Sample 5</td><td colspan="1" rowspan="1">130.2</td><td colspan="1" rowspan="1">1.00</td></tr><tr><td colspan="1" rowspan="1">1:2</td><td colspan="1" rowspan="1">68.8</td><td colspan="1" rowspan="1">1.06</td></tr><tr><td colspan="1" rowspan="1">1:4</td><td colspan="1" rowspan="1">36.4</td><td colspan="1" rowspan="1">1.12</td></tr><tr><td colspan="1" rowspan="1">1:8</td><td colspan="1" rowspan="1">19.0</td><td colspan="1" rowspan="1">1.17</td></tr><tr><td colspan="1" rowspan="1">1:16</td><td colspan="1" rowspan="1">9.6</td><td colspan="1" rowspan="1">1.18</td></tr></table>

Two of the calculated ratios were above the specifications for this study. The package insert includes a statement that not all sera can be diluted linearly within the measuring range of the assay due to differing binding characteristics of the antibodies in the patient samples. The assay measuring range for the EliA CCP is from 0.4 to $\geq 3 4 0$ EliA $\mathrm { U } / \mathrm { m L } /$

c. Traceability, Stability, Expected values (controls, calibrators, or methods): The IgG calibrators are traceable (via an unbroken chain of calibrations) to the International Reference Preparation (IRP) 67/86 of Human Serum Immunoglobulins A, G and M from WHO. New batches of calibrators are compared to a secondary standard (standardized with the IRP) or the IRP directly and adjusted accordingly to meet the correct concentration (6 levels).

d. Detection limit:

The lower limit of the measuring range was determined by measuring dilutions (1:2, 1:4, and 1:8) of the $4 \mu \mathrm { g / L }$ calibrator in the Calibrator Wells. The results in Response Units (RU) were compared with the result of the sample diluent on CCP Wells. The discrimination ability of the assay should be ${ > } 2$ . All samples were measured in triplicate.

<table><tr><td colspan="3" rowspan="1">Results on Calibrator Wells</td></tr><tr><td colspan="1" rowspan="1">Sample ID</td><td colspan="1" rowspan="1">Mean Response Units (RU)</td><td colspan="1" rowspan="1">SD</td></tr><tr><td colspan="1" rowspan="1">Sample Diluent</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Calibrator 4.0</td><td colspan="1" rowspan="1">316</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Calibrator 4.0 at 1:2</td><td colspan="1" rowspan="1">127</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Calibrator 4.0 at 1:4</td><td colspan="1" rowspan="1">89</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Calibrator 4.0 at 1:8</td><td colspan="1" rowspan="1">61</td><td colspan="1" rowspan="1">1.47</td></tr><tr><td colspan="3" rowspan="1">Results on CCP Wells</td></tr><tr><td colspan="1" rowspan="1">Sample ID</td><td colspan="1" rowspan="1">Mean RU</td><td colspan="1" rowspan="1">SD</td></tr><tr><td colspan="1" rowspan="1">Sample Diluent</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">10.6</td></tr></table>

The discrimination ability was 3.8 and the 1:8 dilution of the $4 \mu \mathrm { g / L }$ calibrator could be discriminated from background. The lower limit of the measuring range was set at $0 . 5 ~ { \mu \mathrm { g / L } }$ , corresponding to 0.4 EliA $\mathrm { U } / \mathrm { m L }$ .

e. Hook effect:

Hook effect was analyzed by using dilutions from a highly positive anti-CCP serum sample with an estimated anti-CCP IgG concentration around 4400 $\mathrm { U / m L }$ . The sample was measured in triplicate.

<table><tr><td rowspan=1 colspan=6>Results on Calibrator Wells</td></tr><tr><td rowspan=1 colspan=1>Sample ID</td><td rowspan=1 colspan=1>Mean RU</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>Mean conc.μg/L</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Cal-600</td><td rowspan=1 colspan=1>17533</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>600.9</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=6>Results onCCP Wells</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean RU</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>Mean conc. µg/L</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>Estimated conc.U/mL</td></tr><tr><td rowspan=1 colspan=1>1:25</td><td rowspan=1 colspan=1>22236</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>Over</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>4438</td></tr><tr><td rowspan=1 colspan=1>1:100</td><td rowspan=1 colspan=1>20882</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>Over</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1109</td></tr><tr><td rowspan=1 colspan=1>1:200</td><td rowspan=1 colspan=1>17766</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>Over</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>555</td></tr><tr><td rowspan=1 colspan=1>1:400</td><td rowspan=1 colspan=1>13858</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>251.8</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>277</td></tr></table>

Dilutions showed that no hook effect occurred for this sample. The discrimination ability was 8.4 for the sample compared to the response received for Calibrator 600.

$f .$ Analytical specificity:

The potential interferant and the corresponding blanks were added to two antiCCP positive sera from patients with RA. The spiked samples were tested in triplicate.

<table><tr><td>Additives</td><td>Concentration in raw sample</td><td>Final concentration in diluted sample (1:100)</td><td>Normal Values</td></tr><tr><td>Bilirubin F</td><td>18.8 mg/dL</td><td>0.188</td><td>&lt;1.0</td></tr><tr><td>Bilirubin C</td><td>20 mg/dL</td><td>0.2</td><td>&lt;1.0</td></tr><tr><td>Chyle</td><td>236,000 Units/dL</td><td>2360</td><td>No data</td></tr><tr><td>Hemoglobin</td><td>453 mg/dl</td><td>4.5</td><td>&lt;2.0</td></tr><tr><td>Rheumatoid Factor IgM</td><td>550 IU/ml</td><td>5.5</td><td>&lt;40.0</td></tr></table>

The ratio of the result of the sample spiked with the interfering substance and the sample spiked with a buffer blank was determined:

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3>Positive Sample</td><td rowspan=1 colspan=3>Low Positive Sample</td></tr><tr><td rowspan=2 colspan=1>Additive</td><td rowspan=2 colspan=1>Blank/spikedsample</td><td rowspan=2 colspan=1>Conc.(U/mL)</td><td rowspan=2 colspan=1>CV%</td><td rowspan=1 colspan=1>Ratio</td><td rowspan=2 colspan=1>Conc.(U/mL)</td><td rowspan=2 colspan=1>CV%</td><td rowspan=2 colspan=1>Ratio</td></tr><tr><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>Bilirubin C</td><td rowspan=1 colspan=1>Blank</td><td rowspan=1 colspan=1>67.1</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>13.4</td><td rowspan=1 colspan=1>6.2</td><td rowspan=2 colspan=1>1.01</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>65.6</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>13.5</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=2 colspan=1>Bilirubin F</td><td rowspan=1 colspan=1>Blank</td><td rowspan=1 colspan=1>61.0</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>1.03</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>4.2</td><td rowspan=2 colspan=1>0.95</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>62.9</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>11.8</td><td rowspan=1 colspan=1>13.5</td></tr><tr><td rowspan=2 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>Blank</td><td rowspan=1 colspan=1>63.6</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>0.7</td><td rowspan=2 colspan=1>0.93</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>58.5</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>11.7</td><td rowspan=1 colspan=1>6.7</td></tr><tr><td rowspan=2 colspan=1>Chyle</td><td rowspan=1 colspan=1>Blank</td><td rowspan=1 colspan=1>64.3</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>13.0</td><td rowspan=1 colspan=1>8.5</td><td rowspan=2 colspan=1>1.02</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>64.7</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>13.2</td><td rowspan=1 colspan=1>10.0</td></tr><tr><td rowspan=2 colspan=1>RF</td><td rowspan=1 colspan=1>Blank</td><td rowspan=1 colspan=1>62.5</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>13.5</td><td rowspan=1 colspan=1>9.5</td><td rowspan=2 colspan=1>0.90</td></tr><tr><td rowspan=1 colspan=1>sample</td><td rowspan=1 colspan=1>59.8</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>12.2</td><td rowspan=1 colspan=1>2.1</td></tr></table>

The interfering substances listed did not appear to adversely affect the results of the new device.

g. Assay cut-off:

The purpose of the normal sera studies was to evaluate expected values in the normal population and to confirm the defined cut-off. Samples from 400 apparently healthy Caucasian adult blood donors were measured. The individuals were equally distributed by sex and age.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>EliA U/mL</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>Median</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>Mean + 2 SD</td><td rowspan=1 colspan=1>7.6</td></tr><tr><td rowspan=1 colspan=1>Mean + 3 SD</td><td rowspan=1 colspan=1>10.1</td></tr><tr><td rowspan=1 colspan=1>95tpercentile</td><td rowspan=1 colspan=1>4.3</td></tr><tr><td rowspan=1 colspan=1>99thpercentile</td><td rowspan=1 colspan=1>6.2</td></tr></table>

The results appeared to be equally distributed and not dependent on age or gender. The ${ \dot { 9 } } 9 ^ { \mathrm { t h } }$ percentile lies below the lower limit of the equivocal range of $7 { \cdot } 1 0 \ \mathrm { U / m L }$ .

2. Comparison studies:

a. Method comparison with predicate device: Samples from 55 anti-CCP positive RA patients and 25 non-RA sample were tested.

<table><tr><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1>N = 80</td><td rowspan=1 colspan=3>Diastat anti-CCP</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>EliA CCP</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>54</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>80</td></tr></table>

Positive percent agreement $5 1 / 5 2 \mathrm { ~ x ~ } 1 0 0 = 9 8 . 1 \%$ Negative percent agreement $2 5 / 2 8 \mathrm { ~ x ~ } 1 0 0 = 8 9 . 3 \%$ Overall percent agreement $7 6 / 8 0 \mathrm { ~ x ~ } 1 0 0 = 9 5 \%$

# b. Matrix comparison:

Fifty sets of samples from different donors were tested in double determinations. Each set contained serum, EDTA, heparin and citrate plasma samples taken at the same time from a single donor. All samples were tested and found to be negative for anti-CCP antibodies in all 4 sample types.

Antibodies were spiked into 25 of the sample sets to create 25 positive sample sets. Linear regression comparing the quotas between serum and each type of plasma for the positive samples was performed and showed:

<table><tr><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>r value</td><td rowspan=1 colspan=1>Slope</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>0.9966</td><td rowspan=1 colspan=1>0.9861</td></tr><tr><td rowspan=1 colspan=1>EDTA</td><td rowspan=1 colspan=1>0.9975</td><td rowspan=1 colspan=1>0.9749</td></tr><tr><td rowspan=1 colspan=1>Citrate</td><td rowspan=1 colspan=1>0.9987</td><td rowspan=1 colspan=1>0.9912</td></tr></table>

The data show acceptable results for plasma versus serum in positive and negative samples.

c. Instrument platform comparison For this comparison study, a total of 36 samples distributed over the measuring range were assayed: 4 negative samples, 1 equivocal sample and 31 positive samples. All samples were run on three ImmunoCAP 100 instruments and three ImmunoCAP 250 instruments in two runs and in single replicates. Results of the conformance study are summarized in the figure below:

![](images/3e02739174cf421c27ace5ad36343aeb596cbf4c630100f560c524d0ffc72520.jpg)

Correlation Result: $y { = } 0 . 9 9 \mathrm { x } { + } 1 . 0 2 7 5$ where x is ImmunoCAP 100 and y is ImmunoCAP 250

3. Clinical studies:

a. Clinical sensitivity and specificity: The clinical studies were performed with 534 sera from subjects with clinically confirmed RA $( \mathrm { n } { = } 8 2 )$ ) and 452 other diseases (listed below).

<table><tr><td rowspan=1 colspan=1>Other disease groups</td><td rowspan=1 colspan=1>No. of patients</td><td rowspan=1 colspan=1>No. of positives</td></tr><tr><td rowspan=1 colspan=1>CTD</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>UCTD</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>SLE</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Scleroderma</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Sjögren&#x27;s syndrome</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>MCTD</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Myositis</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>9</td></tr><tr><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Infectious diseases</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>CMV</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>EBV</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>HBV</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>HCV</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>HIV</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Other infectious diseases</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>185</td><td rowspan=1 colspan=1>3</td></tr><tr><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Other</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Osteoarthritis</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Vasculitis</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Autoimmune thyroiddiseases</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Crohn&#x27;s disease</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Ulcerative colitis</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Other misc.</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>147</td><td rowspan=1 colspan=1>3</td></tr></table>

Study results:

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Rheumatoid Arthritis</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>EliA CCPresult</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>87</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>437</td><td rowspan=1 colspan=1>447</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>452</td><td rowspan=1 colspan=1>534</td></tr></table>

Clinical sensitivity: $8 7 . 8 \%$ (72/82) Clinical specificity: $9 6 . 7 \%$ (437/452) Overall agreement: $9 5 . 3 \%$ (509/534)

b. Other clinical supportive data (when a. is not applicable): Not applicable

4. Clinical cut-off: See assay cut-off.

5. Expected values/Reference range:

The expected value in the normal population is negative. The proportion of sera found positive for anti-CCP antibodies using the EliA CCP assay in the adult normal population tested was less than $1 \%$ .

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.